To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
60 patients around the world
Available in Chile, Mexico, United States, Brazil, Spain
Incyte Corporation
60Patients around the world
Requirements for the patient
To 99 Years
All Gender
Medical requirements
Female and male adults and adolescents ≥ 12 years of age with a diagnosis of FOP.
Willingness to avoid pregnancy or fathering children based on the criteria below.
Willing and able to undergo low-dose WBCT (excluding the head) imaging without requiring intubation.
Pregnant or breast-feeding.
CAJIS score ≥ 24.
FOP disease severity that in the investigator's opinion precludes participation.
Any clinically significant medical condition other than FOP that would, in the investigator's judgment, interfere with full participation in the study, pose a significant risk to the participant, or interfere with interpretation of study data.
Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.
